347 related articles for article (PubMed ID: 35679017)
1. JAK in the [Black] Box: A Dermatology Perspective on Systemic JAK Inhibitor Safety.
Elmariah SB; Smith JS; Merola JF
Am J Clin Dermatol; 2022 Jul; 23(4):427-431. PubMed ID: 35679017
[TBL] [Abstract][Full Text] [Related]
2. Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications.
Shalabi MMK; Garcia B; Coleman K; Siller A; Miller AC; Tyring SK
Skin Therapy Lett; 2022 Jan; 27(1):4-9. PubMed ID: 35081305
[TBL] [Abstract][Full Text] [Related]
3. JAK Inhibitor Safety Compared to Traditional Systemic Immunosuppressive Therapies.
Daniele S; Bunick C
J Drugs Dermatol; 2022 Dec; 21(12):1298-1303. PubMed ID: 36468956
[TBL] [Abstract][Full Text] [Related]
4. A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
Bieber T; Feist E; Irvine AD; Harigai M; Haladyj E; Ball S; Deberdt W; Issa M; Grond S; Taylor PC
Adv Ther; 2022 Nov; 39(11):4910-4960. PubMed ID: 36063279
[TBL] [Abstract][Full Text] [Related]
5. A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring.
Samuel C; Cornman H; Kambala A; Kwatra SG
Dermatol Ther (Heidelb); 2023 Mar; 13(3):729-749. PubMed ID: 36790724
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box.
Misra DP; Pande G; Agarwal V
Clin Rheumatol; 2023 Feb; 42(2):621-632. PubMed ID: 36264400
[TBL] [Abstract][Full Text] [Related]
7. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.
Mori S; Ogata F; Tsunoda R
Clin Rheumatol; 2021 Nov; 40(11):4457-4471. PubMed ID: 34554329
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases: A Systematic Review and Meta-Analysis.
Ingrassia JP; Maqsood MH; Gelfand JM; Weber BN; Bangalore S; Lo Sicco KI; Garshick MS
JAMA Dermatol; 2024 Jan; 160(1):28-36. PubMed ID: 37910098
[TBL] [Abstract][Full Text] [Related]
9. Oral Janus kinase inhibitors and venous thromboembolic events in atopic dermatitis: protocols for a case-time control study and a nested case-control study based on the French national health insurance (SNDS) cohort.
Berthe P; Scailteux LM; Lescoat A; Staumont D; Coiffier G; Guéret P; Dupuy A; Oger E; Droitcourt C
BMJ Open; 2022 Sep; 12(9):e059979. PubMed ID: 36130766
[TBL] [Abstract][Full Text] [Related]
10. The suitability of treating atopic dermatitis with Janus kinase inhibitors.
Narla S; Silverberg JI
Expert Rev Clin Immunol; 2022 May; 18(5):439-459. PubMed ID: 35377276
[TBL] [Abstract][Full Text] [Related]
11. Janus Kinase Inhibitors in Atopic Dermatitis: New Perspectives.
Munera-Campos M; Carrascosa JM
Actas Dermosifiliogr; 2023 Sep; 114(8):680-707. PubMed ID: 37105270
[TBL] [Abstract][Full Text] [Related]
12. The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials.
Yoon S; Kim K; Shin K; Kim HS; Kim B; Kim MB; Ko HC; Kim YH
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):52-61. PubMed ID: 37597261
[TBL] [Abstract][Full Text] [Related]
13. Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors: A Systematic Review and Meta-analysis.
Chen TL; Lee LL; Huang HK; Chen LY; Loh CH; Chi CC
JAMA Dermatol; 2022 Nov; 158(11):1254-1261. PubMed ID: 36001310
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.
Wan H; Jia H; Xia T; Zhang D
Dermatol Ther; 2022 Sep; 35(9):e15636. PubMed ID: 35703351
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Risk Stratification of Janus Kinase Inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis.
Narla S; Silverberg JI
Dermatitis; 2024; 35(S1):S24-S38. PubMed ID: 37527229
[No Abstract] [Full Text] [Related]
16. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis.
Alves C; Penedones A; Mendes D; Batel Marques F
Eur J Clin Pharmacol; 2022 Dec; 78(12):1923-1933. PubMed ID: 36207461
[TBL] [Abstract][Full Text] [Related]
17. Safety of Oral Janus Kinase Inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis.
Narla S; Silverberg JI
Dermatitis; 2023; 34(5):366-386. PubMed ID: 36800199
[No Abstract] [Full Text] [Related]
18. Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis.
Sun C; Su Z; Zeng YP
Inflamm Res; 2023 Sep; 72(9):1861-1871. PubMed ID: 37707560
[TBL] [Abstract][Full Text] [Related]
19. Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis.
Wood H; Chandler A; Nezamololama N; Papp K; Gooderham MJ
Int J Dermatol; 2022 Jun; 61(6):746-754. PubMed ID: 34423443
[TBL] [Abstract][Full Text] [Related]
20. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
